LONDON, March 23,
2023 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN),
the global medical technology company, today announces results from
new scientific research that shows its COBLATION Intracapsular
Tonsillectomy (CIT) technique can lead to improved post-operative
outcomes in patients versus total tonsillectomy techniques. The
research was recently published online by OTO Open: The Open
Access Journal of the American Academy of Otolaryngology-Head and
Neck Surgery Foundation.
The research – a systematic literature review with meta-analysis
– evaluated 17 clinical studies on 6,501 paediatric and adult
patients who received either CIT or total tonsillectomy for
recurrent tonsillitis or obstructive sleep apnoea over a
twenty-year period. It demonstrates that, compared to total
tonsillectomy, patients who received CIT presented the following
improved outcomes:
- Fewer post-operative complications: 64% less likely to
experience post-tonsillectomy haemorrhage* (PTH).1
- Reduction in pain severity, duration and post-operative
analgesia use: Pain scores at day one and week one were
significantly lower, average time to pain-free was reduced by 4.2
days, and average duration of analgesia use was reduced by 4.1
days.1
- Faster return to normal activity and diet: On average,
patients reported a return to normal activity 2.8 days faster and a
return to normal diet 3.5 days faster.1
"We are thrilled to share the findings of this meta-analysis,"
said Meghan Mavity, Vice President
and General Manager Global ENT for Smith+Nephew. "The impact that
this technology and technique have on patient outcomes is clear and
reflects our commitment to ensuring surgeons have the tools they
need to make a significant improvement in patients' lives."
COBLATION Intracapsular Tonsillectomy involves the removal of
all, or the majority, of tonsil tissue while maintaining the
integrity of the underlying capsule. By comparison, traditional
total tonsillectomy removes all tonsil tissue as well as the
underlying capsule, which results in exposure of the muscle bed and
the blood vessels that lie within the muscle. CIT is achieved using
COBLATION Technology, proprietary to Smith+Nephew, which creates a
controlled, stable plasma field at a low relative temperature,
resulting in minimal thermal damage and precise removal of
surrounding soft tissue. Intracapsular Tonsillectomy is growing in
popularity with 20% of paediatric otolaryngologists performing this
procedure in the US.2
For more information about COBLATION Intracapsular
Tonsillectomy, please visit
https://www.smith-nephew.com/en/health-care-professionals/products/ear-nose-and-throat/coblation-technology-for-adenotonsillectomy#referencematerials
References
1. Sedgwick MJ, Saunders C, Bateman N. Intracapsular
tonsillectomy using plasma ablation versus total tonsillectomy: a
systematic literature review and meta-analysis. OTO Open.
2023;7:e22.
2. Huoh KC, Haidar YM, Dunn BS. Current status and future
trends: paediatric intracapsular tonsillectomy in the United States. Laryngoscope.
2021;131 Suppl 2:S1–S9.
* For details on Smith+Nephew's COBLATION™ Technology
products, product information, including indications for use,
contraindications, precautions and warnings, please consult the
product's applicable Instructions for Use (IFU) prior to use. Post
Tonsillectomy Haemorrhage (PTH) is a potentially serious
complication that has been reported in literature for both adult
and paediatric patients.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology business focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people's
bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 19,000
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Sports
Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of Covid, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
Covid; economic and financial conditions in the markets we serve,
especially those affecting healthcare providers, payers and
customers (including, without limitation, as a result of Covid);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal and financial compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers (including, without limitation, as a result of Covid);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments;
relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to
natural disasters, weather and climate change related events;
changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC's website at www.
sec.gov, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-evidence-demonstrates-smithnephews-coblation-technology-can-accelerate-patient-recovery-with-fewer-complications-compared-with-total-tonsillectomy-techniques-301778490.html
SOURCE Smith & Nephew plc